Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual…
- Three late-breaking presentations to feature emerging evidence of VRDN-001 efficacy and differentiation - - VRDN-001 10mg/kg proof of concept data from ongoing Phase 1/2 trial in Thyroid Eye Disease selected for late-breaking…